ArticleSignal transduction and targeted therapy2026
Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer.
Abstract read
In one paragraph
Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Xiuping Guo *State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Wensheng Zheng *Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Kaichao Song *State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Tingting Zhang *State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhigang Luo *Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Zhouguang HuiDepartment of VIP Medical Services, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Qingbo ChenState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Yuting QinCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Yanan SunState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Chujuan HuState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Xiaolian TianState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Sitong YangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Ling RenState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Quanyong YuChina Pharmaceutical University, Nanjing, China.
Haoyang YuState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Bozhao LiCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Yingying HeState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Yuanbin LiState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Mingyu PanUniversity of California-Riverside, Riverside, CA, USA.
Yongsheng CheState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. ysche@imb.cams.cn.
Guangjun NieCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center of Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China. niegj@nanoctr.cn.ORCID http://orcid.org/0000-0001-5040-9793
Jiandong JiangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. jiangjiandong@imb.cams.cn.ORCID http://orcid.org/0000-0003-1173-685X
Lulu WangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Beijing Key Laboratory of Key Technologies and Application for Research and Development of New Anti-infective Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. wanglulu@imb.cams.cn.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In triple-negative breast cancer (TNBC), chemotherapy-induced immunogenic cell death (ICD) often fails to trigger truly effective antitumor immunity. This failure primarily stems from the simultaneous release of damage-associated molecular patterns (DAMPs) and immunosuppressive prostaglandin E2 (PGE
Indexed as
CelecoxibDeoxycytidineNanomedicineTriple Negative Breast NeoplasmsAnimalsCell Line, TumorDinoprostoneFemaleGemcitabineHumansImmunogenic Cell DeathMiceProdrugsTumor MicroenvironmentCelecoxibDeoxycytidineDinoprostoneGemcitabineProdrugs
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.